Isotope User Meeting Dates Announced!

Cathy Cutler moderates the Ac-225 User Meeting at the 2019 SNMMI Conference

Cathy Cutler moderates the Ac-225 User Meeting at the 2019 SNMMI Conference

This year the DOE Isotope Program will host three 90-minute virtual isotope user meetings focused on the following emerging alpha-emitters: actinium-225, astatine-211, and lead-212.

The purpose of the meetings is to encourage free discussion and collaboration amongst users of specific isotopes and accelerate their widespread use in medicine.

These webinar-style sessions will feature brief presentations by leading researchers showcasing their latest progress in these emerging fields, followed by interactive panel discussions. Participants are also encouraged to share insights and ask questions during a moderated Q&A segment. 

Click the links below to register for each webinar and add them to your calendar.


Actinium-225 User MeetingKate Dadachova with the University of Saskatchewan

Join us Tuesday, July 28th at 11:00 am ET for our actinium-225 session moderated by Ekaterina (Kate) Dadachova from the University of Saskatchewan.


Researchers presenting and presentation titles include:

  1. Production Effort to Provide Accel.-Produced Ac-225 for Radiotherapy - Presented by Cathy Cutler, DOE Tri-Lab Lead at Brookhaven National Laboratory
  2. Ac-225 Radiopharmaceuticals FDA Perspective - Chemistry, Manufacturing, and Controls - Presented by Ravindra Kasliwal, U.S. Food and Drug Administration
  3. NRC Perspectives on Emerging Radionuclides - Presented by Lisa Dimmick, U.S. Nuclear Regulatory Commission
  4. Radiolabeling Comparison of Accel. Versus Generator Produced Ac-225 - Presented by Vanessa Sanders, Brookhaven National Laboratory
  5. Ac-225 and Bi-213: Two Important Alpha Emitters for the Future of Therapeutics - Presented by Kevin Allen, University of Saskatchewan
  6. Targeted Alpha-Particle Therapy for Acute Myeloid Leukemia - Presented by Joseph Jurcic, Columbia University


Astatine-211 User MeetingScott Wilbur with the University of Washington

Join us Tuesday, July 28th at 1:00 pm ET for our astatine-211 session moderated by Scott Wilbur from the University of Washington. 


Researchers presenting and presentation titles include:

  1. Astatine Studies at Duke: A Ground Level View - Presented by Yutian Feng and Michael Zalutsky, Duke University
  2. Astatine-211: Production Update for the University of Washington - Presented by Yawen Li and Rob Emery, University of Washington
  3. The Dawn of ARTEMISPresented by Sherry Yennello, University of Texas A&M
  4. Astatine-211 Update: University of Pennsylvania - Presented by Mehran Makvandi and Bob Mach, University of Pennsylvania


Lead-212 User MeetingRoy Copping with Oak Ridge National Laboratory

Join us Thursday, July 30th at 11:00 am ET for our lead-212 session moderated by Roy Copping with Oak Ridge National Laboratory. 


Researchers presenting and presentation titles include:

  1. Preclinical Evaluation of Synergistic Anti-tumor Effect from a Combination of Pb-212 Alpha-radiation and Immune Checkpoint Inhibitors - Presented by Mengshi Li, Viewpoint / University of Iowa
  2. Preclinical Evaluation of Pb-212 Based Radiopharmaceutical Therapy of Prostate Cancer - Presented by Sangeeta Ray, Johns Hopkins University
  3. Pb-212-AlphaMedix TM Targeted Alpha Therapy: A Potential Breakthrough in the Treatment of Metastatic SSTR Expressing NET - Presented by Ebrahim Delpassand, RadioMedix, Inc.
  4. Recent Activities in Pb-212 Generator Development at PNNL - Presented by Matt O’Hara, Pacific Northwest National Laboratory